NASDAQ:TSRX - Trius Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.

Receive TSRX News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:TSRX
CUSIP89685K10
Phone+1-781-8608660

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Trius Therapeutics (NASDAQ:TSRX) Frequently Asked Questions

What is Trius Therapeutics' stock symbol?

Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."

Has Trius Therapeutics been receiving favorable news coverage?

Headlines about TSRX stock have trended somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trius Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

What other stocks do shareholders of Trius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trius Therapeutics investors own include Opko Health (OPK), Pharmacyclics (PCYC), InvenSense (INVN), Molycorp (MCPIQ), ACADIA Pharmaceuticals (ACAD), AcelRx Pharmaceuticals (ACRX), Alkermes (ALKS), Alnylam Pharmaceuticals (ALNY), Alexion Pharmaceuticals (ALXN) and Amarin (AMRN).

How do I buy shares of Trius Therapeutics?

Shares of TSRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trius Therapeutics' official website?

The official website for Trius Therapeutics is http://www.triusrx.com/.

How can I contact Trius Therapeutics?

Trius Therapeutics' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.


MarketBeat Community Rating for Trius Therapeutics (NASDAQ TSRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe TSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel